Treatment response and neurofilament light chain levels with long-term patisiran in hereditary transthyretin-mediated amyloidosis with polyneuropathy: 24-month results of an open-label extension study

Simina Ticaua Alnylam Pharmaceuticals, Cambridge, MA, USACorrespondence[email protected]

Emre Aldinca Alnylam Pharmaceuticals, Cambridge, MA, USA

Michael Polydefkisb Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

David Adamsc Neurology Department, AP-HP, CHU Bicêtre, Université Paris-Saclay, Paris-Saclay, France

Teresa Coelhod Centro Hospitalar Universitário Santo António, European Reference Network – EUroNMD, Porto, PortugalView further author information

Mitsuharu Uedae Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan

Cecilia Halea Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information

John Vesta Alnylam Pharmaceuticals, Cambridge, MA, USAView further author information

Paul Nioia Alnylam Pharmaceuticals, Cambridge, MA, USA

Articles from other publishers (1)